NCT04895735 2026-02-02MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland CancerMayo ClinicPhase 2 Active not recruiting45 enrolled
NCT04209660 2025-10-07Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting64 enrolled
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT04576091 2024-12-13Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerNational Cancer Institute (NCI)Phase 1 Active not recruiting7 enrolled